General Proximity, a biotechnology company focused on induced proximity medicines, announced a multi-target oncology collaboration with Daiichi Sankyo on November 12th, 2025. The collaboration will see General Proximity use its OmniTAC platform to discover and characterize novel effector-target pairs for Daiichi Sankyo, with the ultimate aim of developing induced proximity therapeutics for undisclosed oncological conditions.

According to the release, the OmniTAC platform is designed to provide unbiased screening for effector proteins capable of modulating disease-relevant targets. This, in turn, can enable precise, selective modification of disease-driving proteins for targets deemed “traditionally undruggable.”

“Daiichi Sankyo is a leader in oncology research and development, and we are excited to work with such a strong collaborator,” said Armand Cognetta, Founder & CEO, General Proximity, in the release. “This agreement represents an important validation of our novel induced proximity approach and highlights the potential of our OmniTAC discovery platform to deliver innovative solutions for patients.”

Financial details of the transaction have not been disclosed at this time.